Fifth Third Bancorp Coherus Bio Sciences, Inc. Transaction History

Fifth Third Bancorp

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 31, 2023	BUY	$3.74 - $5.45 $415 - $604	111 Added 33.74%	440 $1,000
Q2 2023 Jul 25, 2023	BUY	$3.79 - $8.3 $98 - $215	26 Added 8.58%	329 $1,000
Q1 2023 Apr 24, 2023	SELL	$5.89 - $10.52 $312 - $557	-53 Reduced 14.89%	303 $2,000
Q4 2022 Jan 25, 2023	BUY	$5.69 - $10.07 $625 - $1,107	110 Added 44.72%	356 $0
Q2 2022 Aug 04, 2022	BUY	$5.86 - $13.23 $1,441 - $3,254	246 New	246 $2,000
Q1 2022 Apr 19, 2022	SELL	$10.92 - $16.41 $4,466 - $6,711	-409 Closed	0 $0
Q4 2021 Feb 01, 2022	BUY	$15.81 - $18.99 $4,695 - $5,640	297 Added 265.18%	409 $7,000
Q3 2021 Oct 15, 2021	BUY	$12.68 - $17.79 $1,420 - $1,992	112 New	112 $2,000
Q2 2020 Aug 05, 2020	SELL	$14.43 - $19.16 $253,174 - $336,162	-17,545 Closed	0 $0
Q1 2020 May 05, 2020	BUY	$11.67 - $22.53 $1,096 - $2,117	94 Added 0.54%	17,545 $285,000
Q4 2019 Feb 14, 2020	BUY	$16.33 - $21.37 $30,275 - $39,619	1,854 Added 11.89%	17,451 $314,000
Q3 2019 Nov 14, 2019	BUY	$16.3 - $23.37 $254,231 - $364,501	15,597 New	15,597 $316,000

135

77.9M

40.7K

50.1K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $115M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Fifth Third Bancorp, based on Form 13F filings with the SEC.

Stay updated on Fifth Third Bancorp with notifications on news.